## Bernhard Banas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8174974/publications.pdf

Version: 2024-02-01

81900 69250 6,715 156 39 77 citations g-index h-index papers 165 165 165 10679 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Kidney Transplantation After Rescue Allocation—the Eurotransplant Experience: A Retrospective Multicenter Outcome Analysis. Transplantation, 2022, 106, 1215-1226.	1.0	7
2	Monitoring B cell alloresponses in rats. Journal of Immunological Methods, 2022, 501, 113212.	1.4	0
3	Assessment of Physiological Rat Kidney Ageing—Implications for the Evaluation of Allograft Quality Prior to Renal Transplantation. Metabolites, 2022, 12, 162.	2.9	O
4	Determination of unacceptable <scp>HLA</scp> antigen mismatches in kidney transplant recipients. Hla, 2022, 100, 3-17.	0.6	9
5	Dickkopf 3—A New Indicator for the Deterioration of Allograft Function After Kidney Transplantation. Frontiers in Medicine, 2022, 9, .	2.6	1
6	Genetic loci and prioritization of genes for kidney function decline derived from a meta-analysis of 62 longitudinal genome-wide association studies. Kidney International, 2022, 102, 624-639.	5.2	18
7	The Interplay of NEAT1 and miR-339-5p Influences on Mesangial Gene Expression and Function in Various Diabetic-Associated Injury Models. Non-coding RNA, 2022, 8, 52.	2.6	3
8	Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline. Kidney International, 2021, 99, 926-939.	5.2	42
9	Preformed T cell alloimmunity and HLA eplet mismatch to guide immunosuppression minimization with tacrolimus monotherapy in kidney transplantation: Results of the CELLIMIN trial. American Journal of Transplantation, 2021, 21, 2833-2845.	4.7	27
10	Disruption of Tfh:B Cell Interactions Prevents Antibody-Mediated Rejection in a Kidney Transplant Model in Rats: Impact of Calcineurin Inhibitor Dose. Frontiers in Immunology, 2021, 12, 657894.	4.8	13
11	Renal Function and Patient-Reported Outcomes in Stable Kidney Transplant Patients Following Conversion From Twice-Daily Immediate-Release Tacrolimus to Once-Daily Prolonged-Release Tacrolimus: A 12-Month Observational Study in Routine Clinical Practice in Germany (ADAGIO). Transplantation Proceedings, 2021, 53, 1484-1493.	0.6	7
12	Sonographic 3-D Power Doppler Imaging Enhances Rapid Assessment of Morphologic and Pathologic Arteriovenous Fistula Variations. Ultrasound in Medicine and Biology, 2021, 47, 1484-1494.	1.5	2
13	B-cell activating factor BAFF as a novel alert marker for the immunological risk stratification after kidney transplantation. Immunologic Research, 2021, 69, 487-495.	2.9	2
14	Increased Levels of sCD30 Have No Impact on the Incidence of Early ABMR and Long-Term Outcome in Intermediate-Risk Renal Transplant Patients With Preformed DSA. Frontiers in Medicine, 2021, 8, 778864.	2.6	1
15	Nierenvenenthrombosen. Springer Reference Medizin, 2021, , 1-5.	0.0	O
16	A Prospective Multicenter Trial to Evaluate Urinary Metabolomics for Non-invasive Detection of Renal Allograft Rejection (PARASOL): Study Protocol and Patient Recruitment. Frontiers in Medicine, 2021, 8, 780585.	2.6	3
17	Long-Term Kidney Transplant Outcomes: Role of Prolonged-Release Tacrolimus. Transplantation Proceedings, 2020, 52, 102-110.	0.6	28
18	Zoonotic spillover infections with Borna disease virus 1 leading to fatal human encephalitis, 1999–2019: an epidemiological investigation. Lancet Infectious Diseases, The, 2020, 20, 467-477.	9.1	96

#	Article	IF	CITATIONS
19	Repeated kidney reâ€transplantation—the Eurotransplant experience: a retrospective multicenter outcome analysis. Transplant International, 2020, 33, 617-631.	1.6	14
20	Anti-BAFF Treatment Interferes With Humoral Responses in a Model of Renal Transplantation in Rats. Transplantation, 2020, 104, e16-e22.	1.0	12
21	Contrast-Enhanced Ultrasonography as a Novel Method for the Dynamic Visualization of Blood Flow and Fiber Blockage in Dialyzers: A Feasibility Study. Ultrasound in Medicine and Biology, 2020, 46, 2265-2275.	1.5	3
22	B Cell Activating Factor (BAFF) Is Required for the Development of Intra-Renal Tertiary Lymphoid Organs in Experimental Kidney Transplantation in Rats. International Journal of Molecular Sciences, 2020, 21, 8045.	4.1	8
23	Early conversion to a CNI-free immunosuppression with SRL after renal transplantation—Long-term follow-up of a multicenter trial. PLoS ONE, 2020, 15, e0234396.	2.5	4
24	After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney International, 2020, 98, 1044-1052.	5.2	103
25	Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. Lancet, The, 2020, 395, 1627-1639.	13.7	266
26	Outcomes with Tacrolimus-Based Immunosuppression After Kidney Transplantation from Standardand Extended-Criteria Donors $\hat{a} \in A$ Post Hoc Analysis of the Prospective OSAKA Study. Annals of Transplantation, 2020, 25, e920041.	0.9	1
27	Safe Long-Term Outcome After Kidney Donation in Older Donors: A Single-Center Experience. Annals of Transplantation, 2020, 25, e924235.	0.9	1
28	FO065Dynamics of germinal center formation, follicular T helper cell numbers and donor-specific antibodies in a model of chronic allograft rejection. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
29	Glomerular expression pattern of long non-coding RNAs in the type 2 diabetes mellitus BTBR mouse model. Scientific Reports, 2019, 9, 9765.	3.3	7
30	Preformed Donor-Specific HLA Antibodies in Living and Deceased Donor Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1056-1066.	4.5	49
31	Poor risk factor control in outpatients with diabetes mellitus type 2 in Germany: The DIAbetes COhoRtE (DIACORE) study. PLoS ONE, 2019, 14, e0213157.	2.5	8
32	A urinary metabolite constellation to detect acute rejection in kidney allografts. EBioMedicine, 2019, 48, 505-512.	6.1	9
33	Influence of limited examination conditions on contrast-enhanced sonography for characterising liver lesions. Clinical Hemorheology and Microcirculation, 2019, 71, 267-276.	1.7	26
34	The Case   A 78-year-old woman with acute kidney injury and hemolytic anemia. Kidney International, 2019, 95, 473-474.	5.2	0
35	Analysis of Luminex-based Algorithms to Define Unacceptable HLA Antibodies in CDC-crossmatch Negative Kidney Transplant Recipients. Transplantation, 2018, 102, 969-977.	1.0	12
36	Extended Pancreas Donor Programâ€"The EXPAND Study. Transplantation, 2018, 102, 1330-1337.	1.0	36

#	Article	IF	CITATIONS
37	European Reflections on New Indications for Extracorporeal Photopheresis in Solid Organ Transplantation. Transplantation, 2018, 102, 1279-1283.	1.0	7
38	Long-term expression of glomerular genes in diabetic nephropathy. Nephrology Dialysis Transplantation, 2018, 33, 1533-1544.	0.7	11
39	Clinical validation of a novel enzyme-linked immunosorbent spot assay-based <i>inÂvitro</i> diagnostic assay to monitor cytomegalovirus-specific cell-mediated immunity in kidney transplant recipients: a multicenter, longitudinal, prospective, observational study. Transplant International, 2018, 31, 436-450.	1.6	30
40	Evaluation of adherence and tolerability of prolongedâ€release tacrolimus (Advagrafâ,,¢) in kidney transplant patients in Germany: A multicenter, noninterventional study. Clinical Transplantation, 2018, 32, e13142.	1.6	18
41	CCR7 Is Important for Mesangial Cell Physiology and Repair. Journal of Histochemistry and Cytochemistry, 2018, 66, 7-22.	2.5	3
42	Biomarker-guided Intervention to Prevent Acute Kidney Injury After Major Surgery. Annals of Surgery, 2018, 267, 1013-1020.	4.2	268
43	FO042DETECTION OF RENAL ALLOGRAFT REJECTION BY NMR-BASED URINE METABOLOMICS. Nephrology Dialysis Transplantation, 2018, 33, i35-i36.	0.7	0
44	Generation of TIGIT+ iTregs by Human Regulatory Macrophages before Kidney Transplantation. Transplantation, 2018, 102, S17.	1.0	0
45	1575. Clinical Validation of a Novel ELISpot-based in vitro Diagnostic Assay to Monitor CMV-Specific Cell-Mediated Immunity in SOT and HSCT Immunocompromised Patients. Open Forum Infectious Diseases, 2018, 5, S491-S492.	0.9	0
46	Development of Organized Intra-Graft Lymphocyte Clusters – Role of B Cell Activating Factor BAFF Transplantation, 2018, 102, S716.	1.0	0
47	Clinical Validation of a Novel ELISpot-based in Vitro Diagnostic Assay to Monitor CMV-specific Cell-Mediated Immunity in Kidney Transplant Recipients. Transplantation, 2018, 102, S53.	1.0	0
48	B-Cell Activating Factor BAFF Reflects Patients' immunological Risk Profile after Kidney Transplantation. Transplantation, 2018, 102, S715.	1.0	0
49	Fatal Encephalitic Borna Disease Virus 1 in Solid-Organ Transplant Recipients. New England Journal of Medicine, 2018, 379, 1377-1379.	27.0	106
50	Identification of a urine metabolite constellation characteristic for kidney allograft rejection. Metabolomics, 2018, 14, 116.	3.0	18
51	Non-Invasive Diagnostic of Renal Allograft Rejection Via Urine Metabolites Using NMR-spectroscopy. Transplantation, 2018, 102, S27.	1.0	0
52	TIGIT+ iTregsÂelicited by human regulatory macrophages control T cell immunity. Nature Communications, 2018, 9, 2858.	12.8	101
53	Mehr als ein Navi für Leukozyten: CCR7 als bedeutender Faktor für die mesangiale Physiologie. Nieren- Und Hochdruckkrankheiten, 2018, 47, 131-136.	0.0	0
54	Stellenwert des kontrastmittelverstÃrkten Ultraschalls (CEUS) bei der Nierenbildgebung – Erfahrungen aus einem interdisziplinÃren Ultraschallzentrum. Nieren- Und Hochdruckkrankheiten, 2018, 47, 157-162.	0.0	0

#	Article	IF	CITATIONS
55	Perfusionsbeurteilung bei Nierentransplantaten: Machen digitale Dopplerverfahren den Kontrastmittelultraschall (CEUS) $\tilde{A}\frac{1}{4}$ berfl $\tilde{A}\frac{1}{4}$ ssig?., 2018, 39, .		0
56	Rare and low-frequency coding variants alter human adult height. Nature, 2017, 542, 186-190.	27.8	544
57	Effects of Dopamine Donor Pretreatment on Graft Survival after Kidney Transplantation: A Randomized Trial. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 493-501.	4.5	47
58	Contrast-enhanced ultrasound (CEUS) in renal imaging at an interdisciplinary ultrasound centre: Possibilities of dynamic microvascularisation and perfusion. Clinical Hemorheology and Microcirculation, 2017, 66, 293-302.	1.7	25
59	Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen. Nephrology Dialysis Transplantation, 2017, 32, 730-737.	0.7	39
60	Validation of T-Track $\hat{A}^{\otimes}$ CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patients. BMC Immunology, 2017, 18, 15.	2.2	31
61	Effects of Reduced Kidney Function Because of Living Kidney Donation on Left Ventricular Mass. Hypertension, 2017, 69, 297-303.	2.7	16
62	B-cell activating factor BAFF reflects patients' immunological risk profile after kidney transplantation. Transplant Immunology, 2017, 45, 35-41.	1.2	12
63	Efficacy of Prolonged- and Immediate-release Tacrolimus in Kidney Transplantation: A Pooled Analysis of Two Large, Randomized, Controlled Trials. Transplantation Proceedings, 2017, 49, 2040-2049.	0.6	10
64	Renal allograft rejection, lymphocyte infiltration, and de novo donor-specific antibodies in a novel model of non-adherence to immunosuppressive therapy. BMC Immunology, 2017, 18, 52.	2.2	12
65	MP481LONG TERM REGULATION OF GLOMERULAR GENE EXPRESSION IN DIABETIC NEPHROPATHY. Nephrology Dialysis Transplantation, 2017, 32, iii605-iii606.	0.7	0
66	MP315CLINICAL VALIDATION OF A NOVEL ELISPOT-BASED IN VITRO DIAGNOSTIC ASSAY TO MONITOR CMV-SPECIFIC CELL-MEDIATED IMMUNITY IN KIDNEY TRANSPLANT RECIPIENTS. Nephrology Dialysis Transplantation, 2017, 32, iii542-iii542.	0.7	0
67	Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial. Lancet, The, 2016, 388, 3006-3016.	13.7	129
68	Efficacy and safety of tacrolimus compared with ciclosporin-A in renal transplantation: 7-year observational results. Transplant International, 2016, 29, 307-314.	1.6	17
69	High-urgency kidney transplantation in the Eurotransplant Kidney Allocation System: success or waste of organs? The Eurotransplant 15-year all-centre survey. Nephrology Dialysis Transplantation, 2016, 31, 1515-1522.	0.7	14
70	Infiltration of Macrophages Correlates with Severity of Allograft Rejection and Outcome in Human Kidney Transplantation. PLoS ONE, 2016, 11, e0156900.	2.5	67
71	Strategy to achieve biomarker-driven immunosuppression after solid organ transplantation by an academic-industry partnership within the European BIO-DrIM consortium. Advances in Precision Medicine, 2016, $1,12.$	0.3	1
72	Localization of APOL1 Protein and mRNA in the Human Kidney. Journal of the American Society of Nephrology: JASN, 2015, 26, 339-348.	6.1	113

#	Article	IF	Citations
73	Titer rebound after ABO-incompatible kidney transplantation - is all accommodated for?. Transplant International, 2015, 28, 281-283.	1.6	1
74	Secreted frizzled-related protein 4 predicts progression of autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2015, 31, gfv077.	0.7	9
75	In question: the scientific value of preclinical safety pharmacology and toxicology studies with cell-based therapies. Molecular Therapy - Methods and Clinical Development, 2014, 1, 14026.	4.1	15
76	Clinical management of patients receiving cellâ€based immunoregulatory therapy. Transfusion, 2014, 54, 2336-2343.	1.6	18
77	Metabolic Alkalosis. , 2014, , 77-80.		0
78	Extended pancreas donor program – the EXPAND study rationale and study protocol. Transplantation Research, 2013, 2, 12.	1.5	18
79	Study design of DIACORE (DIAbetes COhoRtE) – a cohort study of patients with diabetes mellitus type 2. BMC Medical Genetics, 2013, 14, 25.	2.1	25
80	Comprehensive morphometric analysis of mononuclear cell infiltration during experimental renal allograft rejection. Transplant Immunology, 2013, 28, 24-31.	1.2	7
81	Lipoxygenase Products in the Urine Correlate with Renal Function and Body Temperature but not with Acute Transplant Rejection. Lipids, 2013, 48, 167-175.	1.7	5
82	Procollagen I-expressing renin cell precursors. American Journal of Physiology - Renal Physiology, 2013, 305, F355-F361.	2.7	7
83	Toll-Like Receptor 4 in Experimental Kidney Transplantation: Early Mediator of Endogenous Danger Signals. Nephron Experimental Nephrology, 2013, 121, e59-e70.	2.2	32
84	OSAKA Trial. Transplantation, 2013, 96, 897-903.	1.0	71
85	Nephron-specific expression of components of the renin–angiotensin–aldosterone system in the mouse kidney. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2012, 13, 46-55.	1.7	11
86	Cyclosporine A Impairs Norepinephrine-Induced Vascular Contractility. Kidney and Blood Pressure Research, 2012, 35, 655-662.	2.0	1
87	Tacrolimus-Based, Steroid-Free Regimens in Renal Transplantation. Transplantation, 2012, 94, 492-498.	1.0	49
88	Elevated urinary sVCAM-1, IL6, sIL6R and TNFR1 concentrations indicate acute kidney transplant rejection in the first 2weeks after transplantation. Cytokine, 2012, 57, 379-388.	3.2	24
89	Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: observational results at 24 and 36â€∫ months after transplantation. Transplant International, 2012, 25, 416-423.	1.6	51
90	Detection of autosomal dominant polycystic kidney disease by NMR spectroscopic fingerprinting of urine. Kidney International, 2011, 79, 1244-1253.	5.2	59

#	Article	IF	Citations
91	Kidney injury moleculeâ€1 and <i>N</i> à€acetylâ€ÃŸâ€ <scp>d</scp> â€glucosaminidase in chronic heart failure: possible biomarkers of cardiorenal syndrome. European Journal of Heart Failure, 2011, 13, 1104-1110.	7.1	114
92	Renal function during rofecoxib therapy in patients with metastatic cancer: retrospective analysis of a prospective phase II trial. BMC Research Notes, 2011, 4, 2.	1.4	13
93	Impact of Toll-like receptor 2 expression in renal allograft rejection. Nephrology Dialysis Transplantation, 2011, 26, 1080-1087.	0.7	18
94	Traditional and Nontraditional Cardiovascular Risk Factors and Estimated Risk for Coronary Artery Disease in Renal Transplant Recipients: A Single-Center Experience. Nephron Clinical Practice, 2011, 119, c227-c235.	2.3	12
95	Hypertonic Stress Promotes the Upregulation and Phosphorylation of Zonula Occludens 1. Nephron Physiology, 2011, 119, p11-p21.	1.2	5
96	Renal Function, Efficacy, and Safety of Sirolimus and Mycophenolate Mofetil After Short-Term Calcineurin Inhibitor-Based Quadruple Therapy in De Novo Renal Transplant Patients: One-Year Analysis of a Randomized Multicenter Trial. Transplantation, 2010, 90, 175-183.	1.0	91
97	Tacrolimus combined with two different corticosteroidâ€free regimens compared with a standard triple regimen in renal transplantation: one year observational results. Clinical Transplantation, 2010, 24, E1-9.	1.6	11
98	High-Level Connexin Expression in the Human Juxtaglomerular Apparatus. Nephron Physiology, 2010, 116, p1-p8.	1.2	35
99	A comprehensive genotype–phenotype interaction of different Toll-like receptor variations in a renal transplant cohort. Clinical Science, 2010, 119, 535-544.	4.3	31
100	Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease. New England Journal of Medicine, 2010, 363, 830-840.	27.0	517
101	Impact of chemokine receptor CX3CR1 in human renal allograft rejection. Transplant Immunology, 2010, 23, 204-208.	1.2	28
102	Is inflammation prior to renal transplantation predictive for cardiovascular and renal outcomes?. Atherosclerosis, 2010, 210, 637-642.	0.8	12
103	Severe anticholinergic drug-induced delirium in a young adult after renal transplantation. Transplant International, 2009, 22, 249-250.	1.6	2
104	Calcineurin inhibitor minimization protocols in liver transplantation. Transplant International, 2009, 22, 49-60.	1.6	84
105	TNF-like weak inducer of apoptosis (TWEAK) induces inflammatory and proliferative effects in human kidney cells. Cytokine, 2009, 46, 24-35.	3.2	112
106	The Mesangial Cell Revisited. Journal of the American Society of Nephrology: JASN, 2009, 20, 1179-1187.	6.1	351
107	No effect of C-reactive protein (CRP) haplotypes on CRP levels and post-transplant morbidity and mortality in renal transplantation. Transplant International, 2008, 21, 452-458.	1.6	9
108	TLR4 Links Podocytes with the Innate Immune System to Mediate Glomerular Injury. Journal of the American Society of Nephrology: JASN, 2008, 19, 704-713.	6.1	189

#	Article	IF	CITATIONS
109	Effect of Membrane Flux and Dialyzer Biocompatibility on Survival in End-Stage Diabetic Nephropathy. Nephron Clinical Practice, 2008, 109, c154-c160.	2.3	13
110	Ultrastructural Evidence of Dermal Gadolinium Deposits in a Patient with Nephrogenic Systemic Fibrosis and End-Stage Renal Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 968-975.	4.5	70
111	Telmisartan, Ramipril, or Both in Patients at High Risk of Vascular Events. New England Journal of Medicine, 2008, 359, 426-427.	27.0	27
112	Efficacy and safety of tacrolimus compared with ciclosporin A in renal transplantation: three-year observational results. Nephrology Dialysis Transplantation, 2008, 23, 2386-2392.	0.7	55
113	Smoking behaviour of patients before and after renal transplantation. Nephrology Dialysis Transplantation, 2007, 23, 1442-1446.	0.7	30
114	Localization of TGF-Î <sup>2</sup> Signaling Intermediates Smad2, 3, 4, and 7 in Developing and Mature Human and Mouse Kidney. Journal of Histochemistry and Cytochemistry, 2007, 55, 275-285.	2.5	27
115	Effect of a Selective Endothelin Receptor A Blocker on Cardiovascular Remodeling in Uninephrectomized Spontaneously Hypertensive Rats of the Stroke-Prone Strain. Kidney and Blood Pressure Research, 2007, 30, 400-407.	2.0	0
116	Target haemoglobin concentrations in chronic kidney disease. Lancet, The, 2007, 369, 1517.	13.7	0
117	Impact of NOD2/CARD15 haplotypes on the outcome after kidney transplantation. Transplant International, 2007, 20, 600-607.	1.6	15
118	RANTES/CCL5 polymorphisms as a risk factor for recurrent acute rejection. Clinical Transplantation, 2007, 21, 385-390.	1.6	25
119	Current concepts and perspectives of immunosuppression in organ transplantation. Langenbeck's Archives of Surgery, 2007, 392, 511-523.	1.9	38
120	Novel Role of Toll-Like Receptor 3 in Hepatitis C-Associated Glomerulonephritis. American Journal of Pathology, 2006, 168, 370-385.	3.8	150
121	Expression of cyclooxygenase-1 and cyclooxygenase-2 in human renal allograft rejection - a prospective study. Transplant International, 2006, 19, 203-212.	1.6	14
122	Expression of the chemokine receptor CXCR3 in human renal allograftsâ€"a prospective study. Nephrology Dialysis Transplantation, 2006, 21, 1373-1381.	0.7	32
123	C-reactive protein as predictor of death in end-stage diabetic nephropathy: Role of peripheral arterial disease. Kidney International, 2005, 68, 217-227.	5.2	20
124	Effects of mycophenolate mofetil on donor-specific antibody formation in renal transplantation. Clinical Transplantation, 2005, 19, 168-174.	1.6	43
125	BK Virus Associated Nephropathy in Native Kidneys of a Heart Allograft Recipient. American Journal of Transplantation, 2005, 5, 1562-1568.	4.7	46
126	Clinical Management of Large Adrenal Cystic Lesions. International Urology and Nephrology, 2005, 37, 767-771.	1.4	30

#	Article	IF	Citations
127	Chemokine Receptor Ccr2 Deficiency Reduces Renal Disease and Prolongs Survival in MRL/lpr Lupus-Prone Mice. Journal of the American Society of Nephrology: JASN, 2005, 16, 3592-3601.	6.1	93
128	Localization and Functional Characterization of Glycosaminoglycan Domains in the Normal Human Kidney as Revealed by Phage Display-Derived Single Chain Antibodies. Journal of the American Society of Nephrology: JASN, 2005, 16, 1279-1288.	6.1	39
129	RANTES gene polymorphisms predict all-cause and cardiac mortality in type 2 diabetes mellitus hemodialysis patients. Atherosclerosis, 2005, 183, 121-129.	0.8	62
130	Alkylphosphocholines: A New Therapeutic Option in Glaucoma Filtration Surgery., 2004, 45, 2619.		17
131	Regulation of Plasma Hemopexin Activity by Stimulated Endothelial or Mesangial Cells. Nephron Physiology, 2004, 96, p1-p10.	1.2	25
132	N-Acetylcysteine in the Prevention of Radiocontrast-Induced Nephropathy: Clinical Trials and End Points. Kidney and Blood Pressure Research, 2004, 27, 161-166.	2.0	12
133	Identification of Novel $\hat{I}^21$ Integrin Binding Sites in the Type 1 and Type 2 Repeats of Thrombospondin-1. Journal of Biological Chemistry, 2004, 279, 41734-41743.	3.4	81
134	Signaling Danger. Journal of the American Society of Nephrology: JASN, 2004, 15, 854-867.	6.1	346
135	Retinoic acid treatment protects MRL/lpr lupus mice from the development of glomerular disease. Kidney International, 2004, 66, 1018-1028.	5.2	79
136	Binding of the chemokine SLC/CCL21 to its receptor CCR7 increases adhesive properties of human mesangial cells. Kidney International, 2004, 66, 2256-2263.	5.2	20
137	Growth arrest specific protein 6/Axl signaling in human inflammatory renal diseases. American Journal of Kidney Diseases, 2004, 43, 286-295.	1.9	59
138	Enhanced ecto-apyrase activity of stimulated endothelial or mesangial cells is downregulated by glucocorticoids in vitro. European Journal of Pharmacology, 2004, 501, 191-198.	3.5	11
139	Effects of chemokines on proliferation and apoptosis of human mesangial cells. BMC Nephrology, 2004, 5, 8.	1.8	38
140	CXCR3 Is Involved in Tubulointerstitial Injury in Human Glomerulonephritis. American Journal of Pathology, 2004, 164, 635-649.	3.8	108
141	Steroid-free organ transplantation. Lancet, The, 2004, 363, 737.	13.7	1
142	Alkylphosphocholines Inhibit Proliferation of Human Retinal Pigment Epithelial Cells., 2003, 44, 3556.		34
143	Bacterial CpG-DNA Aggravates Immune Complex Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2003, 14, 317-326.	6.1	95
144	Angiotensin Inhibition Reduces Glomerular Damage and Renal Chemokine Expression in MRL/lpr Mice. Journal of Pharmacology and Experimental Therapeutics, 2003, 307, 275-281.	2.5	45

#	Article	IF	CITATIONS
145	Everolimus in Cardiac-Transplant Recipients. New England Journal of Medicine, 2003, 349, 2271-2272.	27.0	4
146	Roles of SLC/CCL21 and CCR7 in Human Kidney for Mesangial Proliferation, Migration, Apoptosis, and Tissue Homeostasis. Journal of Immunology, 2002, 168, 4301-4307.	0.8	83
147	Protein kinase C (PKC) dependent induction of tissue factor (TF) by mesangial cells in response to inflammatory mediators and release during apoptosis. British Journal of Pharmacology, 2002, 137, 1116-1124.	5.4	13
148	Modulation of HIV-1 enhancer activity and virus production by cAMP. FEBS Letters, 2001, 509, 207-212.	2.8	13
149	Expression of chemokines and their receptors in nephrotoxic serum nephritis. Nephrology Dialysis Transplantation, 2000, 15, 1046-1053.	0.7	29
150	Chemokine and Chemokine Receptor Expression in a Novel Human Mesangial Cell Line. Journal of the American Society of Nephrology: JASN, 1999, 10, 2314-2322.	6.1	95
151	Immortalization and characterization of human peritoneal mesothelial cells. Kidney International, 1997, 51, 2006-2012.	5.2	8
152	Chemokines and renal disease. Kidney International, 1997, 51, 610-621.	5.2	143
153	Role of Chemokines in Glomerular Diseases. Kidney and Blood Pressure Research, 1996, 19, 270-280.	2.0	11
154	Analysis of the promoter of the human prostatic acid phosphatase gene. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1994, 1217, 188-194.	2.4	12
155	Rapid Steroid Withdrawal after Renal Transplantation Reduces Mortality: Five Year Follow-Up of a Randomized Controlled Trial (Harmony Study) Confirms Long Term Efficacy and Safety. SSRN Electronic Journal, 0, , .	0.4	0
156	Down-Regulation of Human Long Non-Coding RNA LINCO1187 Is Associated with Nephropathies. SSRN Electronic Journal, $0, , \ldots$	0.4	0